Viewing StudyNCT04755283

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
View Study With Definitions
Ignite Creation Date: 2024-05-06 @ 3:47 PM
Last Modification Date: 2024-10-26 @ 1:57 PM
Study NCT ID: NCT04755283
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2024-06-10
First Post: 2021-02-11
Brief Title: Safety and Tolerability of Abelacimab MAA868 vs Rivaroxaban in Patients With Atrial Fibrillation
Sponsor: Anthos Therapeutics Inc
Organization: Anthos Therapeutics Inc
Overview Dates Organization Conditions Design Enrollment Locations Outcomes

Conditions & Keywords Data

Conditions:
Name
Atrial Fibrillation AF
Stroke
Keywords:
Name View
anticoagulation therapy View
randomized View
prospective View
blinded endpoint evaluation View
abelacimab View
MAA868 View
rivaroxaban View
atrial fibrillation View
Factor XI View
stroke View
bleeding events View
anti-coagulant View